抽象的
Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines
Pratap Neelakantan, Jane F Apperley The introduction of the tyrosine kinase inhibitor imatinib, a little over a decade
ago, has greatly improved the prognosis for patients with chronic myeloid leukemia. Now
with the availability of second-generation tyrosine kinase inhibitors we anticipate further
improvements in the outcome of this disease. These agents, namely nilotinib, dasatinib and
bosutinib, have not only been effective at treatment of imatinib-resistant and/or -intolerant
patients, but are increasingly being advocated for upfront usage. In this review, we focus on
nilotinib, its pharmacology, clinical indications and side effects, and suggest guidelines for its
usage.
免责声明: 此摘要通过人工智能工具翻译，尚未经过审核或验证